Engene Therapeutics Inc (ENGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
| 10-2023 | 09-2023 | 07-2023 | 06-2023 | 04-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -99,917 | -3,846 | -17,420 | -3,061 | -12,700 |
| Depreciation Amortization | 175 | N/A | 126 | N/A | 83 |
| Accounts payable and accrued liabilities | 373 | N/A | 968 | N/A | 2,049 |
| Other Working Capital | -517 | 6,746 | -3,143 | 4,805 | -1,134 |
| Other Operating Activity | 75,143 | -4,778 | 1,502 | -2,990 | 1,035 |
| Operating Cash Flow | $-24,743 | $-1,879 | $-17,967 | $-1,245 | $-10,667 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -318 | N/A | -180 | N/A | -23 |
| Other Investing Activity | 0 | -2,530 | 0 | -1,265 | 0 |
| Investing Cash Flow | $-318 | $-2,530 | $-180 | $-1,265 | $-23 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 38,000 | 4,180 | 38,000 | 2,465 | 8,000 |
| Debt Repayment | -1,555 | N/A | -384 | N/A | N/A |
| Common Stock Issued | 56,936 | N/A | 17 | N/A | 17 |
| Other Financing Activity | -7,234 | 0 | -2,327 | 0 | -264 |
| Financing Cash Flow | $86,147 | $4,180 | $35,306 | $2,465 | $7,753 |
| Exchange Rate Effect | 1 | N/A | 1 | N/A | 1 |
| Beginning Cash Position | 20,434 | 314 | 20,434 | 314 | 20,434 |
| End Cash Position | 81,521 | 86 | 37,594 | 269 | 17,498 |
| Net Cash Flow | $61,087 | $-229 | $17,160 | $-45 | $-2,936 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,743 | -1,879 | -17,967 | -1,245 | -10,667 |
| Capital Expenditure | -318 | N/A | -180 | N/A | -23 |
| Free Cash Flow | -25,061 | -1,879 | -18,147 | -1,245 | -10,690 |